Revenue plunges, stock takes a drubbing, but Teva CEO Kåre Schultz still grabs $32.5M in chart-topping compensation
Teva CEO Kåre Schultz hasn’t managed to turn the ship around at Teva, but that didn’t stop him from becoming the highest paid Big Pharma exec we’ve seen so far for 2018 — and we’re almost done counting now.
Teva’s newly filed proxy shows that Schultz’s $20 million cash bonus dropped in his first full year managing the troubled giant, pushing his total compensation package for the year to $32.5 million. That follows $16.2 million in stock awards and options that hit the year before, when Schultz earned $17 million for his compensation package. And at $49.5 million for 14 months of work, that is the top of the curve.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.